Investigating CAR T-Cell Therapy Wait Time and High-Risk Disease Definitions in Myeloma With Samer Al Hadidi, MD, MS, FACP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating CAR T Wait Time and High-Risk Myeloma Definitions With Samer Al Hadidi, MD, MS, FACP At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chimeric antigen receptor (CAR) T-cell therapy and the variability of definitions of high-risk disease in myeloma clinical trials.  
Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Exploring Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer: Josep Tabernero, MD, PhD At the recent American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  
Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma.  
Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the efficacy that HPN217 demonstrated in patients with relapsed/refractory multiple myeloma, including its tolerability and low risk of cytokine release syndrome (CRS).  
Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss...
Multiple Myeloma Trials and Quality News Reporting With Manni Mohyuddin, MBBS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · ASH 2022 Conversations on Multiple Myeloma (Part 1) With Manni Mohyuddin, MBBS At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;14) translocation in multiple myeloma, the characterization of survival end points in clinical trials, and ways to improve the quality of news reporting of oncology clinical trials.  
Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School and Program Director of the Center for Leukemia at Massachusetts General Hospital, served as faculty for Therapy of Acute B-Cell Leukemia: An Evolving Treatment Landscape, a session presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia.
Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Squamous NSCLC Research and Clinical Trials With Mark Kris, MD In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.
Pioneering the Field of Stem Cell Biology With Irving Weissman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Pioneering the Field of Stem Cell Biology With Irving Weissman, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  
Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.
Pioneering the Field of Stem Cell Biology With Irving Weissman, MD
Keira Smith
Expert Analysis
At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  
Additional Advances in Multiple Myeloma Research and Clinical Trials: With Sarah Holstein, MD, PhD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myelom...
Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Highlights from the San Antonio Breast Cancer Symposium At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Devel...
CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · CLL Society, a Valuable Resource for Patients and the Health Care Team: Brian Koffman, MD In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them. 
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be prese...
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.  
Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  
Additional Advances in Waldenstrom Macroglobulinemia Research and Clinical Trials With Morie Gertz, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Recent Updates in Waldenstrom Macroglobulinemia With Morie Gertz, MD In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the Mayo Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.
Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Staying Up To Date On Treatment of Myelofibrosis With John Mascarenhas, MD Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. 
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usuall...

Copyright © 2022 Oncology Data Advisor. All rights reserved.